BriaCell Therapeutics Corp. Warrant expiring 2031 financials
$1.10+3.29%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Apr 30 | Q2 '26 Jan 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$7.6M | -$7.5M |
| Net income | -$7.2M | -$7.2M |
| Net margin | — | — |
| Diluted EPS | $-0.99 | $-2.58 |
| EBITDA | -$7.6M | -$7.5M |
| Operating cash flow | -$7.0M | -$8.0M |
| Free cash flow | -$7.1M | -$8.0M |
| Diluted shares | 7.3M | 2.8M |
Balance sheet
| Period end | Apr 30 | Jan 31 |
|---|---|---|
| Cash & equivalents | $6.9M | $29.9M |
| Short-term investments | $15.9M | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $27.1M | $33.6M |
| Total liabilities | $3.7M | $3.4M |
| Shareholders' equity | $23.4M | $30.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology